Of note, previous studies consistently showed that interactions between PSC-derived HGF and cancer-cell-derived c-MET are the most important mechanism of pancreatic cancer resistance to gemcitabine [28] and targeting the HGF/c-MET axis is a key element in sensitizing the gemcitabine treatment of pancreatic cancer [29]. This evidence concerns the gene MET and familial pancreatic carcinoma.